Dasotraline showed significant improvement in efficacy compared to placebo at week 1 and throughout the study for children aged 6 to 12 years with attention deficit hyperactivity disorder (ADHD) which could be a promising new treatment.
A detailed description of the trial design and the results is published in the Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Robert Goldman, PhD, Sunovion Pharmaceuticals (Marlborough, MA and Fort Lee, NJ), and colleagues from Kennedy Krieger Institute/Johns Hopkins University (Baltimore, MD), New York University Langone Medical Center (New York, NY), and Massachusetts General Hospital (Boston, MA) coauthored the article entitled "Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial."
Dasotraline also showed significant improvement for some secondary efficacy endpoints, including measures of hyperactivity and inattentiveness. The study also assessed the safety of dasotraline treatment and performed subgroup analysis to look for differences in safety and efficacy across subgroups such as age, gender, and use of other treatments for ADHD.
"Over four million children suffer from ADHD. The investigation of new, safe treatments with less side effects is needed for this patient group," says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.